Literature DB >> 22931705

Does extent of resection impact survival in patients bearing glioblastoma?

Nicolas Dea1, Marie-Pierre Fournier-Gosselin, David Mathieu, Philippe Goffaux, David Fortin.   

Abstract

BACKGROUND: The impact of malignant glioma resection on survival is still a matter of controversy. The lack of well-designed prospective studies as well as control of all factors in retrospective studies plays an important role in this debate. Amongst some of these uncontrolled factors, are the inclusion of different histological grades, the lack of objective methods to estimate the extent of resection and unspecified delays in post-operative imaging.
METHODS: We retrospectively reviewed 126 consecutive patients with glioblastoma, operated on by the senior authors at the Centre Hospitalier Universitaire de Sherbrooke, who met the following criteria: >18 years of age, newly diagnosed glioblastoma, pre-operative magnetic resonance imaging (MRI) within 2 weeks prior to surgery, and a post-operative MRI within 72 hours after surgery. Extent of tumour resection was calculated using pre and post-operative tumour delimitation on gadolinium-enhanced T1 MRI in a volumetric analysis.
RESULTS: Applying stringent specific inclusion criteria, 126 patients were retained in the analysis. The median overall survival was 271 days and the median extent of resection was 65%. Patients with more than 90% of tumour resection had a significantly better outcome, improving median survival from 225 to 519 days (P=0.006). Other factors that significantly improved survival were the use of radiotherapy, the number of regimens and type of chemotherapy used.
CONCLUSION: A more aggressive approach combining maximal safe resection and use of salvage chemotherapy seems to confer a survival advantage for glioblastoma patients.

Entities:  

Mesh:

Year:  2012        PMID: 22931705     DOI: 10.1017/s0317167100015377

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  6 in total

Review 1.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

2.  Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Authors:  Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-04-19       Impact factor: 4.130

Review 3.  Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.

Authors:  Jasmina S Redzic; Timothy H Ung; Michael W Graner
Journal:  Pharmgenomics Pers Med       Date:  2014-02-13

4.  Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor.

Authors:  Uros Smrdel; Mara Popovic; Matjaz Zwitter; Emanuela Bostjancic; Andrej Zupan; Viljem Kovac; Damjan Glavac; Drago Bokal; Janja Jerebic
Journal:  Radiol Oncol       Date:  2016-11-10       Impact factor: 2.991

Review 5.  Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.

Authors:  Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

6.  Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma.

Authors:  Luz M Cumba Garcia; Timothy E Peterson; Mario A Cepeda; Aaron J Johnson; Ian F Parney
Journal:  Front Oncol       Date:  2019-07-16       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.